Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
LOGIN
CREATE ACCOUNT
LOGIN
CREATE ACCOUNT
MY TRIALS
REGISTER TRIAL
FAQs
HINTS AND TIPS
DEFINITIONS
Trial Review
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Download to PDF
Trial details imported from ClinicalTrials.gov
For full trial details, please see the original record at
https://clinicaltrials.gov/ct2/show/NCT02580591
Registration number
NCT02580591
Ethics application status
Date submitted
19/10/2015
Date registered
20/10/2015
Date last updated
2/11/2018
Titles & IDs
Public title
Empagliflozin as Adjunctive to Insulin Therapy Over 26 Weeks in Patients With T1DM (EASE-3)
Query!
Scientific title
A Phase III, Randomised, Double Blind, Placebo-controlled, Parallel Group, Efficacy, Safety and Tolerability Trial of Once Daily, Oral Doses of Empagliflozin as Adjunctive to Insulin Therapy Over 26 Weeks in Patients With Type 1 Diabetes Mellitus (EASE-3)
Query!
Secondary ID [1]
0
0
2014-005256-26
Query!
Secondary ID [2]
0
0
1245.72
Query!
Universal Trial Number (UTN)
Query!
Trial acronym
Query!
Linked study record
Query!
Health condition
Health condition(s) or problem(s) studied:
Diabetes Mellitus, Type 1
0
0
Query!
Condition category
Condition code
Metabolic and Endocrine
0
0
0
0
Query!
Diabetes
Query!
Intervention/exposure
Study type
Interventional
Query!
Description of intervention(s) / exposure
Treatment: Drugs - Empagliflozin
Treatment: Drugs - Placebo
Experimental: Empagliflozin low dose -
Experimental: Empagliflozin high dose -
Experimental: Empagliflozin medium dose -
Placebo Comparator: Placebo -
Treatment: Drugs: Empagliflozin
Treatment: Drugs: Placebo
For blinding purposes
Query!
Intervention code [1]
0
0
Treatment: Drugs
Query!
Comparator / control treatment
Query!
Control group
Query!
Outcomes
Primary outcome [1]
0
0
Change From Baseline in Glycated Hemoglobin (HbA1c) at Week 26 for Full Analysis Set (FAS) (Observed Cases [OC])
Query!
Assessment method [1]
0
0
Change from baseline in Glycated hemoglobin (HbA1c) for full analysis set (FAS) (observed cases [OC]) is presented. With regards to efficacy and safety endpoints, the term 'baseline' referred to the last observed measurement prior to administration of any randomized trial medication. Least squares mean is adjusted mean change from baseline.
Query!
Timepoint [1]
0
0
Baseline to week 26
Query!
Primary outcome [2]
0
0
Change From Baseline in Glycated Hemoglobin (HbA1c) at Week 26 for Modified Intention-to-treat Population Set (mITT) (Observed Case (OC) - All Data (AD) (OC-AD))
Query!
Assessment method [2]
0
0
Change from baseline in Glycated hemoglobin (HbA1c) for modified intention-to-treat population set (mITT) (observed case - all data [OC-AD]) is presented. With regards to efficacy and safety endpoints, the term 'baseline' referred to the last observed measurement prior to administration of any randomized trial medication. Least squares mean is adjusted mean change from baseline.
Query!
Timepoint [2]
0
0
Baseline to week 26
Query!
Secondary outcome [1]
0
0
Rate Per Patient-year of Investigator-reported Symptomatic Hypoglycemic Adverse Events (AEs) With Confirmed Plasma Glucose (PG)
Query!
Assessment method [1]
0
0
Rate per patient-year of investigator-reported symptomatic hypoglycemic adverse events (AEs) with confirmed plasma glucose (PG) <54 milligram per deciliter (mg/dL) (<3.0 millimoles per litre (mmol/L)) and/or severe hypoglycemic AEs (i.e. all investigator-reported AEs that had confirmed PG <54 mg/dL [<3.0 mmol/L] with symptoms reported and all severe hypoglycemic events that were confirmed by adjudication) is presented for (i) From week 5 to 26 and (ii) From week 1 to 26. Least squares mean is actually an adjusted event rate. This is key secondary endpoints.
Query!
Timepoint [1]
0
0
Week 5 to Week 26, Week 1 to Week 26
Query!
Secondary outcome [2]
0
0
Change From Baseline in Body Weight at Week 26
Query!
Assessment method [2]
0
0
Change from baseline in body weight is presented With regards to efficacy and safety endpoints, the term 'baseline' referred to the last observed measurement prior to administration of any randomized trial medication. Least squares mean is adjusted mean change from baseline.
Query!
Timepoint [2]
0
0
Baseline to week 26
Query!
Secondary outcome [3]
0
0
Change From Baseline in Total Daily Insulin Dose (TDID) at Week 26
Query!
Assessment method [3]
0
0
Change from baseline in Total daily insulin dose (TDID) is presented. With regards to efficacy and safety endpoints, the term 'baseline' referred to the last observed measurement prior to administration of any randomized trial medication. Least squares mean is adjusted mean change from baseline.
Query!
Timepoint [3]
0
0
Baseline to week 26
Query!
Secondary outcome [4]
0
0
Change From Baseline in Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP) at Week 26
Query!
Assessment method [4]
0
0
Change from baseline in Systolic blood pressure (SBP) and Diastolic blood pressure (DBP) is presented. With regards to efficacy and safety endpoints, the term 'baseline' referred to the last observed measurement prior to administration of any randomized trial medication. Least squares mean is adjusted mean change from baseline.
Query!
Timepoint [4]
0
0
Baseline to week 26
Query!
Eligibility
Key inclusion criteria
Inclusion criteria:
- Signed and dated written informed consent
- Male or female patient receiving insulin for the treatment of documented diagnosis of
type 1 diabetes mellitus (T1DM) > 1 year
- C-peptide value of < 0.7 ng/mL
- Use of Multiple Daily Injections (MDI) of insulin or insulin pump user with total
daily insulin >= 0.3 and <= 1.5 U/kg
- Glycated haemoglobin (HbA1c) >= 7.5% and <= 10.0%
- Good understanding of T1DM
- Age >= 18 years
- Body Mass Index (BMI) >= 18.5 kg/m2
- Estimated glomerular filtration rate >= 30 mL/min/1.73 m2
- Women of child-bearing potential must use highly effective methods of birth control
- Compliance with trial medication administration between 80% and 120% during placebo
run-in period Further inclusion criteria apply
Query!
Minimum age
18
Years
Query!
Query!
Maximum age
No limit
Query!
Query!
Sex
Both males and females
Query!
Can healthy volunteers participate?
No
Query!
Key exclusion criteria
Exclusion criteria:
- History of type 2 diabetes mellitus, maturity onset diabetes of the young (MODY),
pancreatic surgery or chronic pancreatitis
- Pancreas, pancreatic islet cells or renal transplant recipient
- T1DM treatment with any other antihyperglycaemic drug except subcutaneous basal and
bolus insulin within last 3 months
- Occurrence of severe hypoglycaemia within last 3 months and until randomisation
- Occurence of diabetic ketoacidosis within 3 months prior to Visit 1 and until Visit 6
- Irregular sleep/wake cycle
- Acute coronary syndrome, stroke or Transient Ischaemic Attack (TIA) within last 3
months
- Severe gastroparesis
- Brittle diabetes
- Liver disease
- Eating disorders
- Treatment with anti-obesity drugs, weight-loss surgery or aggressive diet regimen
- Treatment with systemic corticosteroids
- Change in dose of thyroid hormones within last 6 weeks and until randomisation
- Cancer or treatment for cancer in the last five years
- Blood dyscrasias or any disorders causing haemolysis or unstable red blood cells
- Women who are pregnant, nursing, or who plan to become pregnant whilst in the trial
- Alcohol or drug abuse
- Intake of an investigational drug in another trial within last 30 days Further
exclusion criteria apply
Query!
Study design
Purpose of the study
Treatment
Query!
Allocation to intervention
Randomised controlled trial
Query!
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Query!
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Query!
Masking / blinding
Blinded (masking used)
Query!
Who is / are masked / blinded?
Query!
Query!
Query!
Query!
Intervention assignment
Parallel
Query!
Other design features
Query!
Phase
Phase 3
Query!
Type of endpoint/s
Query!
Statistical methods / analysis
Query!
Recruitment
Recruitment status
Completed
Query!
Data analysis
Query!
Reason for early stopping/withdrawal
Query!
Other reasons
Query!
Date of first participant enrolment
Anticipated
Query!
Actual
22/12/2015
Query!
Date of last participant enrolment
Anticipated
Query!
Actual
Query!
Date of last data collection
Anticipated
Query!
Actual
20/09/2017
Query!
Sample size
Target
Query!
Accrual to date
Query!
Final
977
Query!
Recruitment in Australia
Recruitment state(s)
NSW,SA,VIC
Query!
Recruitment hospital [1]
0
0
Coffs Endocrine & Diabetes Services - Coffs Harbour
Query!
Recruitment hospital [2]
0
0
Lyell McEwin Hospital - Elizabeth Vale
Query!
Recruitment hospital [3]
0
0
SA Endocrine Research P/L - Keswick
Query!
Recruitment hospital [4]
0
0
Eastern Clinical Research Unit - East Ringwood
Query!
Recruitment postcode(s) [1]
0
0
2450 - Coffs Harbour
Query!
Recruitment postcode(s) [2]
0
0
5112 - Elizabeth Vale
Query!
Recruitment postcode(s) [3]
0
0
5035 - Keswick
Query!
Recruitment postcode(s) [4]
0
0
3135 - East Ringwood
Query!
Recruitment outside Australia
Country [1]
0
0
United States of America
Query!
State/province [1]
0
0
Alabama
Query!
Country [2]
0
0
United States of America
Query!
State/province [2]
0
0
California
Query!
Country [3]
0
0
United States of America
Query!
State/province [3]
0
0
Colorado
Query!
Country [4]
0
0
United States of America
Query!
State/province [4]
0
0
Florida
Query!
Country [5]
0
0
United States of America
Query!
State/province [5]
0
0
Georgia
Query!
Country [6]
0
0
United States of America
Query!
State/province [6]
0
0
Illinois
Query!
Country [7]
0
0
United States of America
Query!
State/province [7]
0
0
Kentucky
Query!
Country [8]
0
0
United States of America
Query!
State/province [8]
0
0
Maryland
Query!
Country [9]
0
0
United States of America
Query!
State/province [9]
0
0
Missouri
Query!
Country [10]
0
0
United States of America
Query!
State/province [10]
0
0
Nevada
Query!
Country [11]
0
0
United States of America
Query!
State/province [11]
0
0
New York
Query!
Country [12]
0
0
United States of America
Query!
State/province [12]
0
0
North Carolina
Query!
Country [13]
0
0
United States of America
Query!
State/province [13]
0
0
Ohio
Query!
Country [14]
0
0
United States of America
Query!
State/province [14]
0
0
Oklahoma
Query!
Country [15]
0
0
United States of America
Query!
State/province [15]
0
0
South Carolina
Query!
Country [16]
0
0
United States of America
Query!
State/province [16]
0
0
Tennessee
Query!
Country [17]
0
0
United States of America
Query!
State/province [17]
0
0
Texas
Query!
Country [18]
0
0
United States of America
Query!
State/province [18]
0
0
Virginia
Query!
Country [19]
0
0
Canada
Query!
State/province [19]
0
0
Alberta
Query!
Country [20]
0
0
Canada
Query!
State/province [20]
0
0
Newfoundland and Labrador
Query!
Country [21]
0
0
Canada
Query!
State/province [21]
0
0
Ontario
Query!
Country [22]
0
0
Canada
Query!
State/province [22]
0
0
Quebec
Query!
Country [23]
0
0
Czechia
Query!
State/province [23]
0
0
Brno
Query!
Country [24]
0
0
Czechia
Query!
State/province [24]
0
0
Holesov
Query!
Country [25]
0
0
Czechia
Query!
State/province [25]
0
0
Hranice
Query!
Country [26]
0
0
Czechia
Query!
State/province [26]
0
0
Prague
Query!
Country [27]
0
0
Finland
Query!
State/province [27]
0
0
Helsinki
Query!
Country [28]
0
0
Finland
Query!
State/province [28]
0
0
Jyväskylä
Query!
Country [29]
0
0
Finland
Query!
State/province [29]
0
0
Pori
Query!
Country [30]
0
0
Finland
Query!
State/province [30]
0
0
Tampere
Query!
Country [31]
0
0
Finland
Query!
State/province [31]
0
0
Turku
Query!
Country [32]
0
0
France
Query!
State/province [32]
0
0
Besancon
Query!
Country [33]
0
0
France
Query!
State/province [33]
0
0
Le Creusot
Query!
Country [34]
0
0
France
Query!
State/province [34]
0
0
Paris
Query!
Country [35]
0
0
France
Query!
State/province [35]
0
0
Poitiers
Query!
Country [36]
0
0
France
Query!
State/province [36]
0
0
Strasbourg
Query!
Country [37]
0
0
France
Query!
State/province [37]
0
0
Toulouse Cédex 04
Query!
Country [38]
0
0
Germany
Query!
State/province [38]
0
0
Bad Mergentheim
Query!
Country [39]
0
0
Germany
Query!
State/province [39]
0
0
Bosenheim
Query!
Country [40]
0
0
Germany
Query!
State/province [40]
0
0
Dortmund
Query!
Country [41]
0
0
Germany
Query!
State/province [41]
0
0
Dresden
Query!
Country [42]
0
0
Germany
Query!
State/province [42]
0
0
Elsterwerda
Query!
Country [43]
0
0
Germany
Query!
State/province [43]
0
0
Essen
Query!
Country [44]
0
0
Germany
Query!
State/province [44]
0
0
Frankfurt
Query!
Country [45]
0
0
Germany
Query!
State/province [45]
0
0
Münster
Query!
Country [46]
0
0
Germany
Query!
State/province [46]
0
0
Neuwied
Query!
Country [47]
0
0
Germany
Query!
State/province [47]
0
0
Rehburg-Loccum
Query!
Country [48]
0
0
Greece
Query!
State/province [48]
0
0
Athens
Query!
Country [49]
0
0
Greece
Query!
State/province [49]
0
0
Ioannina
Query!
Country [50]
0
0
Greece
Query!
State/province [50]
0
0
Nikaia
Query!
Country [51]
0
0
Greece
Query!
State/province [51]
0
0
Thessaloniki
Query!
Country [52]
0
0
Hungary
Query!
State/province [52]
0
0
Budapest
Query!
Country [53]
0
0
Hungary
Query!
State/province [53]
0
0
Debrecen
Query!
Country [54]
0
0
Hungary
Query!
State/province [54]
0
0
Miskolc
Query!
Country [55]
0
0
Hungary
Query!
State/province [55]
0
0
Szekszard
Query!
Country [56]
0
0
Hungary
Query!
State/province [56]
0
0
Szentes
Query!
Country [57]
0
0
Hungary
Query!
State/province [57]
0
0
Zalaegerszeg
Query!
Country [58]
0
0
Ireland
Query!
State/province [58]
0
0
Dublin
Query!
Country [59]
0
0
Italy
Query!
State/province [59]
0
0
Ancona
Query!
Country [60]
0
0
Italy
Query!
State/province [60]
0
0
Brescia
Query!
Country [61]
0
0
Italy
Query!
State/province [61]
0
0
Lucca
Query!
Country [62]
0
0
Italy
Query!
State/province [62]
0
0
Napoli
Query!
Country [63]
0
0
Italy
Query!
State/province [63]
0
0
Roma
Query!
Country [64]
0
0
Italy
Query!
State/province [64]
0
0
Sesto San Giovanni (MI)
Query!
Country [65]
0
0
Italy
Query!
State/province [65]
0
0
Siena
Query!
Country [66]
0
0
Italy
Query!
State/province [66]
0
0
Torino
Query!
Country [67]
0
0
Latvia
Query!
State/province [67]
0
0
Jelgava
Query!
Country [68]
0
0
Latvia
Query!
State/province [68]
0
0
Liepaja
Query!
Country [69]
0
0
Latvia
Query!
State/province [69]
0
0
Ogre
Query!
Country [70]
0
0
Latvia
Query!
State/province [70]
0
0
Riga
Query!
Country [71]
0
0
Latvia
Query!
State/province [71]
0
0
Sigulda
Query!
Country [72]
0
0
Latvia
Query!
State/province [72]
0
0
Talsi
Query!
Country [73]
0
0
Mexico
Query!
State/province [73]
0
0
Aguascalientes
Query!
Country [74]
0
0
Mexico
Query!
State/province [74]
0
0
Guadalajara
Query!
Country [75]
0
0
Netherlands
Query!
State/province [75]
0
0
Alkmaar
Query!
Country [76]
0
0
Netherlands
Query!
State/province [76]
0
0
Almelo
Query!
Country [77]
0
0
Netherlands
Query!
State/province [77]
0
0
Amersfoort
Query!
Country [78]
0
0
Netherlands
Query!
State/province [78]
0
0
Apeldoorn
Query!
Country [79]
0
0
Netherlands
Query!
State/province [79]
0
0
Utrecht
Query!
Country [80]
0
0
New Zealand
Query!
State/province [80]
0
0
Auckland, New Zealand
Query!
Country [81]
0
0
New Zealand
Query!
State/province [81]
0
0
Christchurch
Query!
Country [82]
0
0
Norway
Query!
State/province [82]
0
0
Hamar
Query!
Country [83]
0
0
Norway
Query!
State/province [83]
0
0
Oslo
Query!
Country [84]
0
0
Norway
Query!
State/province [84]
0
0
Stavanger
Query!
Country [85]
0
0
Norway
Query!
State/province [85]
0
0
Tromsø
Query!
Country [86]
0
0
Poland
Query!
State/province [86]
0
0
Chorzow
Query!
Country [87]
0
0
Poland
Query!
State/province [87]
0
0
Gdynia
Query!
Country [88]
0
0
Poland
Query!
State/province [88]
0
0
Katowice
Query!
Country [89]
0
0
Poland
Query!
State/province [89]
0
0
Krakow
Query!
Country [90]
0
0
Poland
Query!
State/province [90]
0
0
Lublin
Query!
Country [91]
0
0
Poland
Query!
State/province [91]
0
0
Olsztyn
Query!
Country [92]
0
0
Poland
Query!
State/province [92]
0
0
Oswiecim
Query!
Country [93]
0
0
Poland
Query!
State/province [93]
0
0
Poznan
Query!
Country [94]
0
0
Poland
Query!
State/province [94]
0
0
Warsaw
Query!
Country [95]
0
0
Poland
Query!
State/province [95]
0
0
Zory
Query!
Country [96]
0
0
Portugal
Query!
State/province [96]
0
0
Braga
Query!
Country [97]
0
0
Portugal
Query!
State/province [97]
0
0
Covilhã
Query!
Country [98]
0
0
Portugal
Query!
State/province [98]
0
0
Lisboa
Query!
Country [99]
0
0
Portugal
Query!
State/province [99]
0
0
Porto
Query!
Country [100]
0
0
Portugal
Query!
State/province [100]
0
0
Viana do Castelo
Query!
Country [101]
0
0
Portugal
Query!
State/province [101]
0
0
Vila Nova de Gaia
Query!
Country [102]
0
0
Romania
Query!
State/province [102]
0
0
Bucharest
Query!
Country [103]
0
0
Romania
Query!
State/province [103]
0
0
Oradea, Bihor County
Query!
Country [104]
0
0
Romania
Query!
State/province [104]
0
0
Timisoara
Query!
Country [105]
0
0
Russian Federation
Query!
State/province [105]
0
0
Moscow
Query!
Country [106]
0
0
Russian Federation
Query!
State/province [106]
0
0
St. Petersburg
Query!
Country [107]
0
0
South Africa
Query!
State/province [107]
0
0
Bryanston
Query!
Country [108]
0
0
South Africa
Query!
State/province [108]
0
0
Cape Town
Query!
Country [109]
0
0
South Africa
Query!
State/province [109]
0
0
Johannesburg
Query!
Country [110]
0
0
South Africa
Query!
State/province [110]
0
0
Pretoria
Query!
Country [111]
0
0
Spain
Query!
State/province [111]
0
0
A Coruña
Query!
Country [112]
0
0
Spain
Query!
State/province [112]
0
0
Granada
Query!
Country [113]
0
0
Spain
Query!
State/province [113]
0
0
Madrid
Query!
Country [114]
0
0
Spain
Query!
State/province [114]
0
0
Sevilla
Query!
Country [115]
0
0
Spain
Query!
State/province [115]
0
0
Valencia
Query!
Country [116]
0
0
Sweden
Query!
State/province [116]
0
0
Göteborg
Query!
Country [117]
0
0
Sweden
Query!
State/province [117]
0
0
Karlskoga
Query!
Country [118]
0
0
Sweden
Query!
State/province [118]
0
0
Lund
Query!
Country [119]
0
0
Sweden
Query!
State/province [119]
0
0
Vällingby
Query!
Country [120]
0
0
Sweden
Query!
State/province [120]
0
0
Ängelholm
Query!
Country [121]
0
0
United Kingdom
Query!
State/province [121]
0
0
Bournemouth
Query!
Country [122]
0
0
United Kingdom
Query!
State/province [122]
0
0
Bradford
Query!
Country [123]
0
0
United Kingdom
Query!
State/province [123]
0
0
Hull
Query!
Country [124]
0
0
United Kingdom
Query!
State/province [124]
0
0
Ipswich
Query!
Country [125]
0
0
United Kingdom
Query!
State/province [125]
0
0
Leicester
Query!
Country [126]
0
0
United Kingdom
Query!
State/province [126]
0
0
London
Query!
Country [127]
0
0
United Kingdom
Query!
State/province [127]
0
0
Middlesbrough
Query!
Country [128]
0
0
United Kingdom
Query!
State/province [128]
0
0
Newcastle Upon Tyne
Query!
Country [129]
0
0
United Kingdom
Query!
State/province [129]
0
0
Nottingham
Query!
Country [130]
0
0
United Kingdom
Query!
State/province [130]
0
0
Nuneaton
Query!
Funding & Sponsors
Primary sponsor type
Commercial sector/Industry
Query!
Name
Boehringer Ingelheim
Query!
Address
Query!
Country
Query!
Other collaborator category [1]
0
0
Commercial sector/Industry
Query!
Name [1]
0
0
Eli Lilly and Company
Query!
Address [1]
0
0
Query!
Country [1]
0
0
Query!
Ethics approval
Ethics application status
Query!
Summary
Brief summary
The study will investigate the efficacy, safety, tolerability and Pharmacokinetic(PK) of 3
doses of empagliflozin compared with placebo over 26 weeks in 960 patients with type 1
diabetes mellitus as adjunctive therapy to insulin
Query!
Trial website
https://clinicaltrials.gov/ct2/show/NCT02580591
Query!
Trial related presentations / publications
Query!
Public notes
Query!
Contacts
Principal investigator
Name
0
0
Boehringer Ingelheim
Query!
Address
0
0
Boehringer Ingelheim
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for public queries
Name
0
0
Query!
Address
0
0
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for scientific queries
Summary Results
For IPD and results data, please see
https://clinicaltrials.gov/ct2/show/NCT02580591
Download to PDF